Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

EORTC Trial results show that Prophylactic Cranial Irradiation in Small Cell Lung Cancer significantly increases survival

16.08.2007
Trial Results published today in the New England Journal of Medicine expected to change medical practice in Europe and US

Small cell lung cancer (SCLC) is an aggressive tumor that constitutes nearly 15% of all newly diagnosed lung cancers. The majority of patients with SCLC present with extensive disease (ED) at diagnosis, meaning that the cancer has spread to other areas of the body.

Without treatment, consisting of chemotherapy, the median survival is two to four months. Despite treatment, in most patients, disease progression will lead to dead within one year. Cancer spreading to the brain is an important cause of death and has a profound negative effect on psychological and physical functioning.

Background
Studies conducted primarily in the 1980 had shown that for patients with limited SCLC and complete response to chemotherapy, prophylactic brain irradiation reduced the risk of brain metastasis and improved survival.

In the EORTC 08993-22993 study, Ben Slotman, MD, PhD, Professor of Radiation Oncology at the VU University medical center in Amsterdam, and his European colleagues from the EORTC Radiation Oncology and Lung Cancer Groups extended the use of prophylactic cranial irradiation (PCI) to patients with extensive SCLC. 286 patients were randomized to either receive prophylactic irradiation or to being observed, following four to six cycles of chemotherapy that induced a response of their SCLC.

Results of the study

One year after being randomized in the trial, only 14.4 % of the patients that received PCI suffered from symptomatic spread of their cancer to the brain, compared with 40.4 % of the patients who did not receive PCI. Moreover, 27.1% of the patients receiving PCI were alive after one year, compared with 13.3% of the patients who were not prophylactically irradiated.

Why this study is important:

“Prophylactic cranial irradiation significantly reduces the risk of symptomatic brain metastases and significantly prolongs survival” according to Prof Slotman. “As this treatment is well tolerated and does not adversely influence quality of life, prophylactic cranial irradiation should now routinely be offered to all SCLC patients with extensive disease whose cancer responds to chemotherapy.”

For Roy S Herbst, MD, PhD, Professor of Medicine in the Department of Thoracic/Head and Neck Medical Oncology, University of Texas/Section Chief of Thoracic Medical oncology at the MD Anderson Cancer center in Houston, Texas, the results of this study represented the most important clinical finding for the treatment of patients with lung cancer presented at ASCO 2007 in June this year. “I expect prophylactic cranial irradiation will be taken up quickly in the US, as well” he commented in an interview during ASCO 2007.

“Furthermore, this trial was impressive because it showed that a standard modality, such as radiation therapy, still has the potential to improve survival. In this era of targeted therapies, we cannot forget that standard modalities can still improve disease outcomes.” he adds.

Moreover, the trial results give weight to the further research hypothesis that thoracic radiotherapy - using the nowadays advanced radiotherapy techniques - might be beneficial to this pretreated patient group as well - a hypothesis Prof Ben Slotman and colleagues are preparing to test in clinical randomized trial to run in The Netherlands, the UK and possibly more European countries.

“The challenge in the future remains how to integrate the current modalities with the newer targeted modalities. This EORTC trial shows once again that in clinical cancer research, pursuing a multidisciplinary research agenda can be crucial for improving patient survival.” explains Françoise Meunier, MD, PhD, Director General of the EORTC.

Reference:
Slotman, B.; Faivre-Finn, C. (2007). Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer. NEJM 357: 664-672.
For further information about the study, please contact:
Ben J Slotman, MD, PhD
Department of Radiation Oncology
VU University Medical Center in Amsterdam – The Netherlands
Tel.: +31 20 4440414 Email: bj.slotman@vumc.nl
For further information about the EORTC, please contact:
Françoise Meunier, MD, PhD
Director General, EORTC
Avenue E. Mounier 83/11
B – 1200 Brussels / Belgium
Email: Francoise.Meunier@eortc.be
About the EORTC:
Created in 1962, the European Organisation for Research and Treatment of Cancer (EORTC) is a not-for-profit international cancer research organisation under the Belgian law.
The EORTC has the mission to develop, conduct, coordinate and stimulate translational and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patients’ quality of life. The ultimate goal of the EORTC is to improve the standard of cancer treatment in Europe, through the evaluation of new drugs and other innovative approaches, and to test more effective therapeutic strategies, using drugs which are already commercially available, or surgery or radiotherapy.
The EORTC has the aim to facilitate the passage of experimental discoveries into state-of-the-art treatment by keeping to a minimum the time lapse between the discovery of new anti-cancer agents and the implementation of their therapeutic benefit for patients with cancer.

The EORTC promotes multidisciplinary cancer research in Europe and is linked to other leading biomedical research organisations around the world. EORTC research takes place in over 300 hospitals, universities and cancer centers in 32 countries, and the unique network of investigators of the EORTC comprises more than 2000 clinicians collaborating on a voluntary basis in 19 multidisciplinary groups.

For any further information related to the research activities of the EORTC, please consult the EORTC website: www.eortc.be

Nicole Heine | alfa
Further information:
http://www.eortc.be

More articles from Health and Medicine:

nachricht Second cause of hidden hearing loss identified
20.02.2017 | Michigan Medicine - University of Michigan

nachricht Prospect for more effective treatment of nerve pain
20.02.2017 | Universität Zürich

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Impacts of mass coral die-off on Indian Ocean reefs revealed

21.02.2017 | Earth Sciences

Novel breast tomosynthesis technique reduces screening recall rate

21.02.2017 | Medical Engineering

Use your Voice – and Smart Homes will “LISTEN”

21.02.2017 | Trade Fair News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>